Asthma exacerbation with fluticasone propionate/formoterol fumarate combination therapy versus its individual components

S. Dissanayake, M. Lomax, K. Kaiser, T. McIver (Cambridge, United Kingdom; Muttenz, Switzerland)

Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Session: Asthma treatment: efficacy and safety
Session type: Thematic Poster Session
Number: 2096
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Dissanayake, M. Lomax, K. Kaiser, T. McIver (Cambridge, United Kingdom; Muttenz, Switzerland). Asthma exacerbation with fluticasone propionate/formoterol fumarate combination therapy versus its individual components. Eur Respir J 2012; 40: Suppl. 56, 2096

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Fluticasone propionate/formoterol fumarate combination therapy is more effective than fluticasone propionate alone in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Fluticasone propionate/formoterol fumarate improves asthma control and reduces exacerbations compared with fluticasone
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013

Fluticasone propionate/formoterol fumarate combination therapy is as effective as fluticasone propionate/salmeterol xinafoate, but has a more rapid onset of action in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Initial maintenance therapy with fluticasone propionate/ salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002

Fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy has comparable efficacy to fluticasone propionate/salmeterol xinafoate (FLUT/SAL) in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011


Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013

Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 292s
Year: 2005

Achievement of total control of asthma in clinical practice using the combination of inhaled salmeterol and fluticasone propionate
Source: Eur Respir J 2006; 28: Suppl. 50, 616s
Year: 2006

Treatment effectiveness and exacerbations during one year with seretide compared to fluticasone propionate and salmeterol in mild-to-moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 176s
Year: 2001

Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma
Source: Eur Respir J 2007; 29: 682-689
Year: 2007



Once-daily, high-dose inhaled fluticasone propionate and salmeterol in patients having moderate asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 125s
Year: 2004

Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently in the treatment of asthma
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with moderate to severe asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with mild to moderate asthma
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009

Efficacy of high-dose inhaled fluticasone propionate in Indian patients having moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 305s
Year: 2002

Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


Impulse oscillometry in evaluation therapy with combination fluticasone propionate and salmeterol in asthma patients
Source: Annual Congress 2007 - New insight into the pathophysiology of asthma
Year: 2007


Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/ fluticasone propionate combination (seretide) and salmeterol
Source: Eur Respir J 2004; 24: Suppl. 48, 291s
Year: 2004

Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD
Source: Eur Respir J 2002; 20: Suppl. 38, 386s
Year: 2002